Pharmacotherapy for pediatric sleep disturbances: Current patterns of use and target populations for controlled clinical trials

被引:9
|
作者
Rosen, CL
Owens, JA
Scher, MS
Glaze, DG
机构
[1] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Div Clin Epidemiol & Biostat, Cleveland, OH 44106 USA
[3] Brown Univ, Rhode Isl Hosp, Sect Behav Pediat, Providence, RI USA
[4] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Div Neurol, Cleveland, OH 44106 USA
[5] Baylor Coll Med, Texas Childrens Hosp, Dept Pediat, Houston, TX USA
[6] Baylor Coll Med, Texas Childrens Hosp, Dept Neurol, Houston, TX USA
来源
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL | 2002年 / 63卷
关键词
pediatric; sleep; insomnia; sleep disturbance;
D O I
10.1016/S0011-393X(02)80103-5
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The systematic study of pharmacologic treatment of sleep disturbances in children requires both careful selection of patients and a thorough and consistent diagnostic approach. This article examines information pertinent to advancing these efforts by considering the prevalence and significance of pediatric sleep disturbances; reviewing current patterns of use of medication for childhood sleep disturbances; and identifying patient populations in whom pharmacotherapy is likely to be appropriate and controlled clinical studies should be conducted. This review reinforces the need to identify safe and effective pharmacologic agents for treating pediatric sleep disturbances and to clearly define the indications and prescribing parameters for such medications. Several medications for pediatric sleep disturbances are commonly prescribed despite a paucity of data to support their efficacy and tolerability. Furthermore, virtually no information is available to guide decisions about appropriate medication doses or duration of therapy in pediatric patients. Finally, despite the fact that pharmacologic therapies for pediatric sleep disturbances have not been well studied to date, it is clear that they fill an important void in the management of sleep disorders in children and deserve continued consideration and evaluation. Recent increases in awareness of the importance of evaluating pediatric responses to medications and advances in techniques for studying the effects of psychotropics offer optimism that the efficacy and tolerability of sleep medicines will be significantly enhanced.
引用
收藏
页码:B53 / B66
页数:14
相关论文
共 35 条
  • [31] Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia:: results of a randomised, placebo-controlled clinical trial
    Sabatowski, R
    Gálvez, R
    Cherry, DA
    Jacquot, F
    Vincent, E
    Maisonobe, P
    Versavel, M
    PAIN, 2004, 109 (1-2) : 26 - 35
  • [32] Insomnia as a mediating therapeutic target for depressive symptoms: A sub-analysis of participant data from two large randomized controlled trials of a digital sleep intervention
    Henry, Alasdair L.
    Miller, Christopher B.
    Emsley, Richard
    Sheaves, Bryony
    Freeman, Daniel
    Luik, Annemarie, I
    Littlewood, Donna L.
    Saunders, Kate E. A.
    Kanady, Jennifer C.
    Carl, Jenna R.
    Davis, Michelle L.
    Kyle, Simon D.
    Espie, Colin A.
    JOURNAL OF SLEEP RESEARCH, 2021, 30 (01)
  • [33] Access to Chimeric Antigen Receptor T Cell Clinical Trials in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult Acute Lymphobastic Leukemia Patients
    Hall, Anurekha G.
    Winestone, Lena E.
    Sullivan, Erin M.
    Wu, Qian
    Lamble, Adam J.
    Walters, Mark C.
    Aguayo-Hiraldo, Paibel
    Conde, Lourdes Baez
    Coker, Tumaini R.
    Dornsife, Dana
    Keating, Amy K.
    Merino, Diana M.
    Ramsey, Bonnie
    Park, Julie R.
    Agrawal, Anurag K.
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (06): : 1 - 7
  • [34] Use of a Qualification Phantom for PET Brain Imaging in a Multicenter Consortium: A Collaboration Between the Pediatric Brain Tumor Consortium and the SNMMI Clinical Trials Network
    Fahey, Frederic
    Christiana, Paul
    Zukotynski, Katherine
    Sexton-Stallone, Briana
    Kiss, Christina
    Clarke, Bonnie
    Onar-Thomas, Arzu
    Poussaint, Tina Young
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (05) : 677 - 682
  • [35] Improving Sleep to Address Co-Occurring Substance Use Disorder and Chronic Pain: Exploring the Potential of the Orexin (Hypocretin) System as a Clinical Target
    Mun, Chung Jung
    Reid, Matthew J.
    Sarandos, Sarah
    Elam, Kit K.
    Li, Celine Mylx
    Strickland, Justin C.
    CURRENT ADDICTION REPORTS, 2024, 11 (06) : 952 - 964